NEPH (Nephros) E10: $-0.40 (As of Mar. 2026)


NEPH Nephros Inc NEPH
63 GF Score
Price $3.61
GF Value $2.87
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros E10?

Nephros NEPH +9.39% 63 E10 is $-0.40 as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 63/100 and a GF Value™ of $2.87 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nephros's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.40 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Nephros was 63.00% per year. The lowest was 14.00% per year. And the median was 37.80% per year.

As of today (2026-06-27), Nephros's current stock price is $3.61. Nephros's E10 for the quarter that ended in Mar. 2026 was $-0.40. Nephros's Shiller PE Ratio of today is .


Nephros  (NAS:NEPH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nephros E10 Related Terms


Nephros E10 Historical Data

* Premium members only.

The historical data trend for Nephros's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephros E10 Chart

Nephros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.46 -1.30 -1.07 -0.55 0.00

Nephros Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.46 -0.44 0.00 -0.40

NEPH vs MLSS, HBIO, FEMY: E10 Comparison

For the Medical Instruments & Supplies subindustry, Nephros's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephros Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nephros's Shiller PE Ratio falls into.


NEPH
63GF Score
Nephros Inc NEPH
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nephros E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nephros's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.01/330.2130*330.2130
=0.010

Current CPI (Mar. 2026) = 330.2130.

Nephros Quarterly Data

per share eps CPI Adj_EPS
201606 -0.180 241.018 -0.247
201609 -0.090 241.428 -0.123
201612 -0.090 241.432 -0.123
201703 -0.090 243.801 -0.122
201706 -0.090 244.955 -0.121
201709 -0.090 246.819 -0.120
201712 0.180 246.524 0.241
201803 -0.270 249.554 -0.357
201806 -0.100 251.989 -0.131
201809 -0.080 252.439 -0.105
201812 -0.100 251.233 -0.131
201903 -0.200 254.202 -0.260
201906 -0.140 256.143 -0.180
201909 -0.100 256.759 -0.129
201912 -0.020 256.974 -0.026
202003 -0.130 258.115 -0.166
202006 -0.190 257.797 -0.243
202009 -0.120 260.280 -0.152
202012 -0.080 260.474 -0.101
202103 -0.060 264.877 -0.075
202106 -0.120 271.696 -0.146
202109 -0.120 274.310 -0.144
202112 -0.110 278.802 -0.130
202203 -0.190 287.504 -0.218
202206 -0.110 296.311 -0.123
202209 -0.300 296.808 -0.334
202212 -0.090 296.797 -0.100
202303 -0.030 301.836 -0.033
202306 -0.040 305.109 -0.043
202309 -0.020 307.789 -0.021
202312 -0.060 306.746 -0.065
202403 -0.020 312.332 -0.021
202406 -0.030 314.175 -0.032
202409 0.020 315.301 0.021
202412 0.030 315.605 0.031
202503 0.050 319.799 0.052
202506 0.020 322.561 0.020
202509 0.030 324.800 0.030
202512 0.000 324.054 0.000
202603 0.010 330.213 0.010

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.40 mean?
Nephros (NEPH) has a E10 of $-0.40 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nephros and its competitors.
Is Nephros' E10 too high?
Nephros' current E10 is $-0.40. Overall, Nephros has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' E10 compare to MLSS and HBIO?
Nephros' E10 of $-0.40 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nephros and its competitors. Nephros's current E10 is $-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.87, compared to a current price of $3.61 — trading 25.8% above its estimated fair value. The current E10 is $-0.40. Nephros' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nephros (NEPH), the current E10 is $-0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.61 is trading 25.8% above its estimated GF Value™ of $2.87. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • E10: $-0.40
  • GF Value™: $2.87 vs. price of $3.61 (25.8% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
63GF Score

Get the complete analysis for NEPH

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.61
Price
$2.87
GF Value